Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) Net Income towards Common Stockholders (2016 - 2025)

Palisade Bio has reported Net Income towards Common Stockholders over the past 16 years, most recently at -$10.0 million for Q4 2025.

  • Quarterly Net Income towards Common Stockholders fell 194.92% to -$10.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$17.9 million through Dec 2025, down 23.39% year-over-year, with the annual reading at -$18.1 million for FY2025, 21.48% down from the prior year.
  • Net Income towards Common Stockholders was -$10.0 million for Q4 2025 at Palisade Bio, down from -$2.9 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $5.1 million in Q3 2021 and troughed at -$31.7 million in Q2 2021.
  • The 5-year median for Net Income towards Common Stockholders is -$3.5 million (2024), against an average of -$4.7 million.
  • The largest YoY upside for Net Income towards Common Stockholders was 377.75% in 2021 against a maximum downside of 1615.07% in 2021.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at $5.1 million in 2021, then crashed by 175.23% to -$3.9 million in 2022, then grew by 18.0% to -$3.2 million in 2023, then dropped by 7.19% to -$3.4 million in 2024, then crashed by 194.92% to -$10.0 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Net Income towards Common Stockholders are -$10.0 million (Q4 2025), -$2.9 million (Q3 2025), and -$2.8 million (Q2 2025).